1388 related articles for article (PubMed ID: 26685004)
1. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
2. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
3. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.
Smith SG; Chen R; Kjarsgaard M; Huang C; Oliveria JP; O'Byrne PM; Gauvreau GM; Boulet LP; Lemiere C; Martin J; Nair P; Sehmi R
J Allergy Clin Immunol; 2016 Jan; 137(1):75-86.e8. PubMed ID: 26194544
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
5. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
6. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic inflammation assessed by induced sputum in corticosteroid-dependent asthma.
Tarodo de la Fuente P; Romagnoli M; Carlsson L; Godard P; Bousquet J; Chanez P
Respir Med; 1999 Mar; 93(3):183-9. PubMed ID: 10464876
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for severe eosinophilic asthma.
Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
[TBL] [Abstract][Full Text] [Related]
12. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
Menzies-Gow A; Flood-Page P; Sehmi R; Burman J; Hamid Q; Robinson DS; Kay AB; Denburg J
J Allergy Clin Immunol; 2003 Apr; 111(4):714-9. PubMed ID: 12704348
[TBL] [Abstract][Full Text] [Related]
14. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
15. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
17. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma.
Fowler SJ; Tavernier G; Niven R
J Allergy Clin Immunol; 2015 Mar; 135(3):822-4.e2. PubMed ID: 25445828
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
[TBL] [Abstract][Full Text] [Related]
19. Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis.
Dorman SC; Efthimiadis A; Babirad I; Watson RM; Denburg JA; Hargreave FE; O'Byrne PM; Sehmi R
Am J Respir Crit Care Med; 2004 Mar; 169(5):573-7. PubMed ID: 14630618
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma.
de Groot JC; van Roon EN; Storm H; Veeger NJ; Zwinderman AH; Hiemstra PS; Bel EH; ten Brinke A
J Allergy Clin Immunol; 2015 Mar; 135(3):670-5.e3. PubMed ID: 25617224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
